Drug interactions of Infigratinib

Strong and Moderate CYP3A Inhibitors:

Concomitant use may significantly increase the plasma concentration of infigratinib and should be avoided.

Strong and Moderate CYP3A Inducers:

Concomitant use may significantly decrease the plasma concentration of infigratinib and should be avoided.

Gastric Acid-Reducing Agents (Proton Pump Inhibitors, H2 Receptor Antagonists, Antacids):

Concomitant use may decrease the plasma concentration of infigratinib and should be avoided. If the use of H2 receptor antagonists or antacids cannot be avoided, the administration times should be staggered.

Infigratinib has no clinically significant effect on the pharmacokinetics of CYP3A4 substrates.

FDA，2021.05